Protocol Ledger

NCT05252988 · Phase II · ACTIVE NOT RECRUITING

Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib

Interventional Phase II clinical trial protocol NCT05252988 sponsored by Spanish Breast Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-31 Enrollment: 177 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05252988
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)177 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05252988
Protocol FieldVerified Registry Value
NCT IdentifierNCT05252988
Consolidated Lead SponsorSpanish Breast Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment177 participants (ACTUAL)
Registered Start Date2022-08-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05252988
Hospital Research SiteLocationSite Profile
Hospital General Universitario de ElcheElche, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI